Name | ARQ-087 dihydrochloride |
---|---|
Synonyms |
Benzo[h]quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-N-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-, (6R)-, hydrochloride (1:2)
(6R)-6-(2-Fluorophenyl)-N-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine dihydrochloride U6B7J0L31Q |
Description | Derazantinib (ARQ-087) dihydrochloride is an ATP competitive and orally activeFGFR inhibitor (IC50s: 1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3). Derazantinib dihydrochloride inhibits FGFR phosphorylation. Derazantinib dihydrochloride inhibits tumor growth in multiple xenograft models[1][2]. |
---|---|
Related Catalog | |
Target |
1.8 nM for FGFR2, 4.5 nM for FGFR1 and 3 nM[1] |
References |
Molecular Formula | C29H31Cl2FN4O |
---|---|
Molecular Weight | 541.487 |
Exact Mass | 540.185913 |